Legionnaire’s Disease in Compromised Hosts

• Fanny Lanternier ^[1] ; Florence Ader ^[2] ; Benoit Pilmis ^[1] ; Emilie Catherinot ^[3] ; Sophie Jarraud ^[2] ; Olivier Lortholary ^[1]
  1. [1] Paris Descartes University

     Paris Descartes University

     París, Francia

     
  2. [2] Claude Bernard University Lyon 1

     Claude Bernard University Lyon 1

     Arrondissement de Lyon, Francia

     
  3. [3] Hôpital Foch

     Hôpital Foch

     Arrondissement de Nanterre, Francia

     

  Mostrar afiliaciones +
• Localización: Infectious disease clinics of North America, ISSN 0891-5520, Vol. 31, Nº. 1, 2017, págs. 123-135
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Legionnaire’s disease (LD) is mainly reported in apparently immunocompetent patients. Among them, risk factors include chronic lung disease and smoking. However, LD is also well reported among immunocompromised patients, particularly those treated with anti–tumor necrosis factor alpha therapy, patients with hematological malignancy, and transplant patients. This article discusses the available data on immunity against Legionella spp, epidemiology, clinical presentation, diagnosis, and treatment of LD in immunocompromised patients.